25
Require MHRA to clarify phage standards for clinical trials and GMP acquisition
Recommendation
We recommend that the MHRA sets out what standard of phages will be required for UK clinical trials and how GMP will be acquired by UK produced phages if they cannot be assessed by a clinical trial. This guidance should be published within six months of the publication of this report.
Paragraph Reference
106
Government Response
A response document is linked to this report, dated 1 March 2024. Response attribution to this recommendation has not been verified. Read the response document.
Source
Report
First Report - The antimicrobial potential of bacteriophages
03 Jan 2024
HC 328
Addressee Bodies
Department for Science, Innovation and Technology
Timeline
Recommendation age
2.7 yrs
Report published
03 Jan 2024